Clopidogrel Tablet
Product Images NDC 16714-052

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 16714-052). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

505 (Clopidogrel 75mg 30s)

Label for Clopidogrel Tablets USP 75 mg oral tablets by NorthStar RxLLC. The label includes the NDC 16714-052-01, packaging count of 30 tablets, storage instructions, and manufacturing details. It specifies each tablet contains 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base. The label also notes the medication guide availability and manufacturing location in India.*

FDA Label Image

505 (Clopidogrel 75mg 500s)

Label for Clopidogrel Tablets, USP 75 mg oral tablets marketed by NorthStar Rx LLC. The label includes dosage strength, dispensing info for pharmacists, storage instructions, and manufacturer details (Macleods Pharmaceuticals Ltd., India). It also features barcodes and an expiration date of 07/2022.*

FDA Label Image

505 (Clopidogrel 75mg 90s)

Label for Clopidogrel Tablets, USP 75 mg oral tablets by NorthStar Rx LLC. The label states each tablet contains 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base. It includes storage instructions, package size of 90 tablets, manufacturer information, and barcode.*

FDA Label Image

189 (Clopidogrel Fig 3)

A forest plot chart showing hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various subgroups including Heparin/LMWH use, Aspirin dosage, GPIIb/IIIa antagonist use, Beta-Blocker use, and ACE Inhibitor use. The chart illustrates the relative favorability of Clopidogrel versus placebo for each subgroup and overall outcome.*

FDA Label Image

Figure-1 (Clopidogrel Figure 01)

A horizontal error bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of Clopidogrel. The graph compares four PPIs—Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg—displaying mean changes and 90% confidence intervals relative to Clopidogrel administered alone.*

FDA Label Image

Figure-2 (Clopidogrel Figure 02)

A line graph depicting cumulative event rates of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. The graph compares two groups: one receiving placebo plus aspirin and the other receiving clopidogrel plus aspirin, showing lower event rates for the clopidogrel group. A p-value of 0.00009 is noted, indicating statistical significance between groups.*

FDA Label Image

Figure-4 (Clopidogrel Figure 04)

A Kaplan-Meier survival curve showing percentage of deaths before first discharge among patients over 28 days since randomization. It compares placebo and clopidogrel groups, indicating fewer deaths in the clopidogrel group with a 7% proportional risk reduction (p=0.03).*

FDA Label Image

146 (Clopidogrel Figure 05)

Kaplan-Meier curve showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days after randomization. The chart compares outcomes between patients treated with Clopidogrel and those given a placebo, indicating events in each group and a noted 9% proportional risk reduction for Clopidogrel (p = 0.002).*

FDA Label Image

Fig-7 (Clopidogrel Figure 07)

A line graph showing the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up, comparing aspirin and clopidogrel. The graph shows two curves labeled 'ASPIRIN' and 'CLOPIDOGREL,' with a statistical significance value of P=0.045.*

FDA Label Image

Figure-3 (Clopidogrel Figure 3)

A forest plot chart displaying hazard ratios with 95% confidence intervals comparing the effect of Clopidogrel versus placebo across various subgroups such as age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. The plot shows sample sizes and event counts for Clopidogrel and placebo groups, indicating differences in outcomes among these subgroups.*

FDA Label Image

Figure-6 (Clopidogrel Figure 6)

A forest plot displaying the odds ratios and 99% confidence intervals comparing Clopidogrel versus placebo across various subgroups such as gender, age, time since onset, systolic blood pressure, heart rate, and use of fibrinolytic agents. The horizontal axis ranges from 0.6 to 1.3, indicating favorability towards Clopidogrel or placebo.*

FDA Label Image

Figure-8 (Clopidogrel Figure 8)

A hazard ratio plot comparing Clopidogrel and Aspirin across qualifying conditions: Stroke, MI (myocardial infarction), PAD (peripheral artery disease), and overall. The x-axis represents the hazard ratio with a 95% confidence interval. Data points are shown for each condition, indicating treatment favorability between Clopidogrel and Aspirin with numeric values of patient counts and event percentages.*

FDA Label Image

Structure (Clopidogrel Structure)

Chemical structure of Clopidogrel sulfate, showing its molecular arrangement with sulfur-containing rings, chlorine-substituted aromatic ring, and characteristic ester groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.